[go: up one dir, main page]

NO20060535L - Aztreonam-L-lysin og fremgangsmater for fremstilling av dette - Google Patents

Aztreonam-L-lysin og fremgangsmater for fremstilling av dette

Info

Publication number
NO20060535L
NO20060535L NO20060535A NO20060535A NO20060535L NO 20060535 L NO20060535 L NO 20060535L NO 20060535 A NO20060535 A NO 20060535A NO 20060535 A NO20060535 A NO 20060535A NO 20060535 L NO20060535 L NO 20060535L
Authority
NO
Norway
Prior art keywords
aztreonam
lysine
preparing
methods
lysine salt
Prior art date
Application number
NO20060535A
Other languages
English (en)
Other versions
NO333985B1 (no
Inventor
Claude Singer
Csaba Szabo
Viktor Gyollai
Istvan Bodi
Original Assignee
Teva Pharmaceutical Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Usa Inc filed Critical Teva Pharmaceutical Usa Inc
Publication of NO20060535L publication Critical patent/NO20060535L/no
Publication of NO333985B1 publication Critical patent/NO333985B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

Oppfinnelsen angår L-lysinsaltet av aztieonam og fremgangsmåter for fremstilling av L-lysinsaltet av aztreonam.
NO20060535A 2003-07-02 2006-02-01 Fremgangsmåte for fremstilling av aztreonam-L-lysin NO333985B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48486103P 2003-07-02 2003-07-02
US55009804P 2004-03-04 2004-03-04
PCT/US2004/021237 WO2005005424A1 (en) 2003-07-02 2004-07-01 Aztreonam l-lysine and methods for the preparation thereof

Publications (2)

Publication Number Publication Date
NO20060535L true NO20060535L (no) 2006-02-01
NO333985B1 NO333985B1 (no) 2013-11-04

Family

ID=34068199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060535A NO333985B1 (no) 2003-07-02 2006-02-01 Fremgangsmåte for fremstilling av aztreonam-L-lysin

Country Status (10)

Country Link
US (2) US7262293B2 (no)
JP (1) JP4741487B2 (no)
AU (1) AU2004256124B2 (no)
BR (1) BRPI0411691A (no)
CA (2) CA2733145C (no)
DE (1) DE112004001191B4 (no)
ES (1) ES2304078B2 (no)
IL (1) IL172802A (no)
NO (1) NO333985B1 (no)
WO (1) WO2005005424A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DK1353647T3 (da) 2000-12-27 2011-06-14 Gilead Sciences Inc Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner
WO2004013133A1 (en) * 2002-08-05 2004-02-12 TEVA Gyógyszergyár Részvénytársaság Preparation of aztreonam
WO2004103999A1 (en) * 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
BRPI0411691A (pt) * 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
WO2006122253A1 (en) * 2005-05-09 2006-11-16 Sicor, Inc. Process for making aztreonam
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923998A (en) * 1977-03-14 1990-05-08 Fujisawa Pharmaceutical Company, Ltd. Cephem and cepham compounds and processes for preparation thereof
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4946838A (en) * 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4652651A (en) * 1983-05-31 1987-03-24 Hoffmann-La Roche Inc. Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid intermediates via catalytic ester cleavage
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4675398A (en) 1985-08-16 1987-06-23 E. R. Squibb & Sons, Inc. Copper-mediated oximation reaction
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
JP2653856B2 (ja) * 1988-11-08 1997-09-17 科学技術振興事業団 アミノ酸過酸化物の測定方法及び測定装置
US5254681A (en) * 1989-08-02 1993-10-19 Consiglio Nazionale Delle Ricerche Process for preparing monobactames and their intermediate product
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
PL165700B1 (pl) 1991-10-15 1995-01-31 Pan Sposób wytwarzania kwasu 32/2-amtnotiazoiilo-4/-2/1 -t-butoksykarbonylo- 1 -metyloetoksylmino/octowego
DE19652284A1 (de) * 1996-12-16 1998-06-18 Hoechst Schering Agrevo Gmbh Neue Gene codierend für Aminosäure-Deacetylasen mit Spezifität für N-Acetyl-L-Phosphinothricin, ihre Isolierung und Verwendung
EP1180546B1 (en) * 1999-04-27 2011-06-29 Takeda Pharmaceutical Company Limited Human cell lines showing stable expression of cytochromes p450
JP4320922B2 (ja) * 1999-06-04 2009-08-26 住友化学株式会社 エステラーゼ遺伝子及びその利用
AU1572101A (en) 1999-11-08 2001-06-06 Pharmacia & Upjohn Company Admixture of linezolid and other antibacterial agents
AUPQ872300A0 (en) * 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DK1353647T3 (da) * 2000-12-27 2011-06-14 Gilead Sciences Inc Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
ES2252471T3 (es) * 2001-06-29 2006-05-16 H. Lundbeck A/S Nuevos derivados de heteroarilo, su preparacion y uso.
CN1545514A (zh) 2001-08-27 2004-11-10 阿拉宾度药业有限公司 β型晶体无水氨曲南的生产方法
DE60220424T2 (de) * 2001-09-14 2008-03-06 Novo Nordisk A/S NEUE LIGANDEN FÜR DIE HisB10 Zn2+ STELLEN DES INSULIN-HEXAMERS IN DER R-KONFORMATION
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
EP1444210B1 (en) * 2001-11-03 2009-02-18 AstraZeneca AB Qunazoline derivatives as antitumor agents
CN1596114A (zh) * 2001-11-13 2005-03-16 三维药物公司 取代的1,4－苯并二氮杂䓬类及其在治疗癌症中的应用
WO2004013133A1 (en) * 2002-08-05 2004-02-12 TEVA Gyógyszergyár Részvénytársaság Preparation of aztreonam
EP1413603A1 (en) 2002-10-25 2004-04-28 Titecs Japan Corporation Vibration-damping material composition
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) * 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2004103999A1 (en) * 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
BRPI0411691A (pt) * 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação

Also Published As

Publication number Publication date
BRPI0411691A (pt) 2006-12-26
JP2007521306A (ja) 2007-08-02
ES2304078B2 (es) 2009-09-16
JP4741487B2 (ja) 2011-08-03
CA2733145A1 (en) 2005-01-20
US20050032775A1 (en) 2005-02-10
CA2531170A1 (en) 2005-01-20
AU2004256124B2 (en) 2011-04-28
US7358093B2 (en) 2008-04-15
WO2005005424B1 (en) 2005-04-14
AU2004256124A1 (en) 2005-01-20
NO333985B1 (no) 2013-11-04
DE112004001191T5 (de) 2009-04-23
US20070167424A1 (en) 2007-07-19
CA2531170C (en) 2011-05-10
DE112004001191B4 (de) 2017-11-09
ES2304078A1 (es) 2008-09-01
US7262293B2 (en) 2007-08-28
CA2733145C (en) 2012-06-19
IL172802A0 (en) 2006-06-11
IL172802A (en) 2011-10-31
WO2005005424A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
NO345046B1 (no) Oral doseringsform
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20092609L (no) Tannate salt of rasagiline
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
EA200801372A1 (ru) Способы получения замещенных пиримидинов
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
NO20072473L (no) Fremgangsmate for fremstilling av kinolinforbindelser og oppnadde produkter
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
HRP20150163T1 (xx) Postupak za proizvodnju n-supstituiranih 2-cijanopirolidina
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
NO20055741D0 (no) Nye kjemiske forbindelser
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.